CXCL8 and neoplasm: As a consequence, sudemycin treatment inhibits RELA activity, both basal and induced by CD40L-IL4 stimulus, and decreases the expression of several target genes related to inflammation and tumor invasion, such as IL8, MMP9 and CCL4. All these results suggest that sudemycin could disrupt tumor microenvironment interactions that are often related to chemoresistance and disease relapses [46].